Aimee Demsky
Acute Care · Dallas, TXNPI 1417532409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,340, 2.3 times the $586 reported in 2021. Among acute care clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$757
- Novartis$490
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$476
- Actelion Pharmaceuticals US, Inc.$336
- Kestra Medical Technology Services, Inc.$271
- Sanofi-aventis U.S. LLC$257
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,424100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 38 | $757 |
| Novartis | 29 | $490 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $476 |
| Actelion Pharmaceuticals US, Inc. | 14 | $336 |
| Kestra Medical Technology Services, Inc. | 10 | $271 |
| Sanofi-aventis U.S. LLC | 16 | $257 |
| Amgen | 14 | $233 |
| Pfizer | 10 | $205 |
| Novo Nordisk | 8 | $186 |
| E.r. Squibb & Sons, L.L.C. | 7 | $181 |
| Boehringer Ingelheim | 5 | $118 |
| Bridgebio Pharma, Inc. | 4 | $113 |
| Johnson & Johnson | 6 | $108 |
| AstraZeneca | 6 | $105 |
| Bayer | 4 | $98 |
| Amarin Pharma, Inc. | 4 | $85 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Alnylam Pharmaceuticals Inc. | 3 | $57 |
| Abiomed | 1 | $53 |
| Biosense Webster, Inc. | 2 | $44 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Philips North America LLC | 1 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| GSK | 1 | $22 |
| Vital Connect, Inc | 1 | $12 |
How this compares
$4,424 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $105,980 |
| EntrestoSacubitril/Valsartan | 27 | $45,909 |
| XareltoRivaroxaban | 30 | $32,347 |
| MultaqDronedarone Hcl | 13 | $16,369 |
| Repatha SureclickEvolocumab | 16 | $8,738 |
| Metoprolol Succinate | 192 | $2,770 |
| Flecainide Acetate | 20 | $986 |
| Rosuvastatin Calcium | 51 | $816 |
| Atorvastatin Calcium | 100 | $750 |
| Nifedipine ErNifedipine | 17 | $460 |
| Losartan Potassium | 66 | $439 |
| Lisinopril | 46 | $420 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $355 |
| Ezetimibe | 15 | $334 |
| Niacin ErNiacin | 13 | $325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $205 | $105,980118 claims |
| NovartisEntresto | $490 | $45,90927 claims |
| Johnson & JohnsonXarelto | $108 | $32,34730 claims |
| Sanofi-aventis U.S. LLCMultaq | $257 | $16,36913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.
Other acute care in Dallas
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Martha LibertyDallas$28K
- Rachael SchneiderDallas$20K
- Peter TriporoDallas$15K
- Mario PadillaDallas$13K
- Toni SmithDallas$10K
- Christie MorrisonSan Antonio$225K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.